Spyre Therapeutics (SYRE) Change in Intangibles (2025 - 2026)

Spyre Therapeutics (SYRE) posted Change in Intangibles of $30.0 million for Q1 2026, up 328.57% on a QoQ basis from $7.0 million in Q2 2025.

Spyre Therapeutics (SYRE) Change in Intangibles (2025 - 2026) Analysis & Trends

Spyre Therapeutics' Change in Intangibles history runs 2 years deep, the most recent figure standing at $30.0 million for Q1 2026.

Quarterly Change in Intangibles changed N/A year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (changed N/A YoY) and the FY2025 annual result came in at $7.0 million, changed N/A from the prior year.
Change in Intangibles was $30.0 million for Q1 2026 at Spyre Therapeutics, up from $7.0 million in the prior quarter.
Across five years, Change in Intangibles topped out at $30.0 million in Q1 2026 and bottomed at $7.0 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Spyre Therapeutics	259.59 Mn	259.59 Mn	-	30.00 Mn

Download Data